Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Cytotoxic T-lymphocyte protein 4 (Cytotoxic T-lymphocyte-associated antigen 4) (CTLA-4) (CD antigen CD152)

 CTLA4_HUMAN             Reviewed;         223 AA.
P16410; A0N1S0; E9PDH0; O95653; Q0PP65; Q52MC1; Q53TD5; Q5S005;
Q8WXJ1; Q96P43; Q9UKN9;
01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
10-JAN-2003, sequence version 3.
28-FEB-2018, entry version 200.
RecName: Full=Cytotoxic T-lymphocyte protein 4;
AltName: Full=Cytotoxic T-lymphocyte-associated antigen 4;
Short=CTLA-4;
AltName: CD_antigen=CD152;
Flags: Precursor;
Name=CTLA4; Synonyms=CD152;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), TISSUE
SPECIFICITY, ALTERNATIVE SPLICING, AND VARIANT ALA-17.
PubMed=1713603;
Harper K., Balzano C., Rouvier E., Mattei M.-G., Luciani M.-F.,
Golstein P.;
"CTLA-4 and CD28 activated lymphocyte molecules are closely related in
both mouse and human as to sequence, message expression, gene
structure, and chromosomal location.";
J. Immunol. 147:1037-1044(1991).
[2]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
PubMed=11735222; DOI=10.1006/geno.2001.6655;
Ling V., Wu P.W., Finnerty H.F., Agostino M.J., Graham J.R., Chen S.,
Jussiff J.M., Fisk G.J., Miller C.P., Collins M.;
"Assembly and annotation of human chromosome 2q33 sequence containing
the CD28, CTLA4, and ICOS gene cluster: analysis by computational,
comparative, and microarray approaches.";
Genomics 78:155-168(2001).
[3]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), VARIANT ALA-17,
ALTERNATIVE SPLICING, AND POLYMORPHISM.
PubMed=18595775; DOI=10.1016/j.clim.2008.05.006;
Gu M., Kakoulidou M., Giscombe R., Pirskanen R., Lefvert A.K.,
Klareskog L., Wang X.;
"Identification of CTLA-4 isoforms produced by alternative splicing
and their association with myasthenia gravis.";
Clin. Immunol. 128:374-381(2008).
[4]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
Wu P.W., Ling V.;
"Full length sequence of hCTLA4 cDNA.";
Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases.
[5]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
NIEHS SNPs program;
Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
PubMed=15815621; DOI=10.1038/nature03466;
Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
Waterston R.H., Wilson R.K.;
"Generation and annotation of the DNA sequences of human chromosomes 2
and 4.";
Nature 434:724-731(2005).
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
TISSUE=Lung;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[8]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-223.
TISSUE=Lymphocyte;
PubMed=3220103; DOI=10.1002/eji.1830181206;
Dariavach P., Mattei M.-G., Golstein P., Lefranc M.-P.;
"Human Ig superfamily CTLA-4 gene: chromosomal localization and
identity of protein sequence between murine and human CTLA-4
cytoplasmic domains.";
Eur. J. Immunol. 18:1901-1905(1988).
[9]
NUCLEOTIDE SEQUENCE [MRNA] OF 38-223 (ISOFORM 5).
TISSUE=Lymph node;
Oaks M.K.;
Submitted (FEB-1997) to the EMBL/GenBank/DDBJ databases.
[10]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 140-223, AND TISSUE SPECIFICITY.
PubMed=10493833; DOI=10.1006/geno.1999.5930;
Ling V., Wu P.W., Finnerty H.F., Sharpe A.H., Gray G.S., Collins M.;
"Complete sequence determination of the mouse and human CTLA4 gene
loci: cross-species DNA sequence similarity beyond exon borders.";
Genomics 60:341-355(1999).
[11]
FUNCTION.
PubMed=1714933; DOI=10.1084/jem.174.3.561;
Linsley P.S., Brady W., Urnes M., Griosmaire L.S., Damle N.K.,
Ledbetter J.A.;
"CTLA-4 is a second receptor for the B cell activation antigen B7.";
J. Exp. Med. 174:561-569(1991).
[12]
PHOSPHORYLATION AT TYR-201.
PubMed=9175836; DOI=10.1016/S1074-7613(00)80346-5;
Shiratori T., Miyatake S., Ohno H., Nakaseko C., Isono K.,
Bonifacino J.S., Saito T.;
"Tyrosine phosphorylation controls internalization of CTLA-4 by
regulating its interaction with clathrin-associated adaptor complex
AP-2.";
Immunity 6:583-589(1997).
[13]
PHOSPHORYLATION AT TYR-201.
PubMed=9813138; DOI=10.1006/bbrc.1998.9559;
Schneider H., Schwartzberg P.L., Rudd C.E.;
"Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and
regulates PI 3-kinase binding to T-cell antigen CTLA-4.";
Biochem. Biophys. Res. Commun. 252:14-19(1998).
[14]
PHOSPHORYLATION AT TYR-201 BY JAK2.
PubMed=10842319;
DOI=10.1002/(SICI)1097-4644(20000801)78:2<241::AID-JCB7>3.0.CO;2-K;
Chikuma S., Murakami M., Tanaka K., Uede T.;
"Janus kinase 2 is associated with a box 1-like motif and
phosphorylates a critical tyrosine residue in the cytoplasmic region
of cytotoxic T lymphocyte associated molecule-4.";
J. Cell. Biochem. 78:241-250(2000).
[15]
POLYMORPHISM.
PubMed=12724780; DOI=10.1038/nature01621;
Ueda H., Howson J.M., Esposito L., Heward J., Snook H.,
Chamberlain G., Rainbow D.B., Hunter K.M., Smith A.N., Di Genova G.,
Herr M.H., Dahlman I., Payne F., Smyth D., Lowe C., Twells R.C.,
Howlett S., Healy B., Nutland S., Rance H.E., Everett V., Smink L.J.,
Lam A.C., Cordell H.J., Walker N.M., Bordin C., Hulme J., Motzo C.,
Cucca F., Hess J.F., Metzker M.L., Rogers J., Gregory S.,
Allahabadia A., Nithiyananthan R., Tuomilehto-Wolf E., Tuomilehto J.,
Bingley P., Gillespie K.M., Undlien D.E., Ronningen K.S., Guja C.,
Ionescu-Tirgoviste C., Savage D.A., Maxwell A.P., Carson D.J.,
Patterson C.C., Franklyn J.A., Clayton D.G., Peterson L.B.,
Wicker L.S., Todd J.A., Gough S.C.;
"Association of the T-cell regulatory gene CTLA4 with susceptibility
to autoimmune disease.";
Nature 423:506-511(2003).
[16]
GLYCOSYLATION AT ASN-113 AND ASN-145.
PubMed=16002699; DOI=10.4049/jimmunol.175.2.996;
Darlington P.J., Kirchhof M.G., Criado G., Sondhi J., Madrenas J.;
"Hierarchical regulation of CTLA-4 dimer-based lattice formation and
its biological relevance for T cell inactivation.";
J. Immunol. 175:996-1004(2005).
[17]
FUNCTION, AND TISSUE SPECIFICITY.
PubMed=16551244; DOI=10.1146/annurev.immunol.24.021605.090535;
Teft W.A., Kirchhof M.G., Madrenas J.;
"A molecular perspective of CTLA-4 function.";
Annu. Rev. Immunol. 24:65-97(2006).
[18]
SUBCELLULAR LOCATION.
PubMed=18468488; DOI=10.1016/j.it.2008.02.011;
Valk E., Rudd C.E., Schneider H.;
"CTLA-4 trafficking and surface expression.";
Trends Immunol. 29:272-279(2008).
[19]
PHARMACEUTICAL.
PubMed=19426230; DOI=10.1111/j.1600-065X.2009.00780.x;
Linsley P.S., Nadler S.G.;
"The clinical utility of inhibiting CD28-mediated costimulation.";
Immunol. Rev. 229:307-321(2009).
[20]
STRUCTURE BY NMR OF 37-161, AND DISULFIDE BONDS.
PubMed=9228944; DOI=10.1038/nsb0797-527;
Metzler W.J., Bajorath J., Fenderson W., Shaw S.Y., Constantine K.L.,
Naemura J., Leytze G., Peach R.J., Lavoie T.B., Mueller L.,
Linsley P.S.;
"Solution structure of human CTLA-4 and delineation of a CD80/CD86
binding site conserved in CD28.";
Nat. Struct. Biol. 4:527-531(1997).
[21]
X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 36-161 IN COMPLEX WITH CD86,
SUBUNIT, AND DISULFIDE BONDS.
PubMed=11279501; DOI=10.1038/35069112;
Schwartz J.C., Zhang X., Fedorov A.A., Nathenson S.G., Almo S.C.;
"Structural basis for co-stimulation by the human CTLA-4/B7-2
complex.";
Nature 410:604-608(2001).
[22]
X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 36-161 IN COMPLEX WITH CD80,
SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-113 AND ASN-145.
PubMed=11279502; DOI=10.1038/35069118;
Stamper C.C., Zhang Y., Tobin J.F., Erbe D.V., Ikemizu S., Davis S.J.,
Stahl M.L., Seehra J., Somers W.S., Mosyak L.;
"Crystal structure of the B7-1/CTLA-4 complex that inhibits human
immune responses.";
Nature 410:608-611(2001).
[23]
X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 38-161, DISULFIDE BONDS, AND
SUBUNIT.
Schonfeld D.L., Matschiner G., Chatwell L., Trentmann S.,
Schlehuber S., Hohlbaum A., Skerra A.;
"High affinity molecular recognition and functional blockade of CTLA-4
by an engineered human lipocalin.";
Submitted (JAN-2008) to the PDB data bank.
[24]
X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 36-161, GLYCOSYLATION AT
ASN-113, SUBUNIT, AND DISULFIDE BONDS.
PubMed=21156796; DOI=10.1074/jbc.M110.182394;
Yu C., Sonnen A.F., George R., Dessailly B.H., Stagg L.J., Evans E.J.,
Orengo C.A., Stuart D.I., Ladbury J.E., Ikemizu S., Gilbert R.J.,
Davis S.J.;
"Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4
(CTLA-4) receptor triggering.";
J. Biol. Chem. 286:6685-6696(2011).
[25] {ECO:0000244|PDB:5TRU}
X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 37-154 IN COMPLEX WITH
THERAPEUTIC ANTIBODY IPILIMUMAB, SUBUNIT, INTERACTION WITH CD80; CD86
AND ICOSLG, SUBCELLULAR LOCATION, TOPOLOGY, DISULFIDE BONDS, AND
MUTAGENESIS OF VAL-45; LEU-47; SER-49; ARG-70; LYS-130; GLU-132;
TYR-139 AND ILE-143.
PubMed=28484017; DOI=10.1073/pnas.1617941114;
Ramagopal U.A., Liu W., Garrett-Thomson S.C., Bonanno J.B., Yan Q.,
Srinivasan M., Wong S.C., Bell A., Mankikar S., Rangan V.S.,
Deshpande S., Korman A.J., Almo S.C.;
"Structural basis for cancer immunotherapy by the first-in-class
checkpoint inhibitor ipilimumab.";
Proc. Natl. Acad. Sci. U.S.A. 114:E4223-E4232(2017).
[26]
VARIANT ALA-17, AND INVOLVEMENT IN IDDM12.
PubMed=9259273; DOI=10.1093/hmg/6.8.1275;
Marron M.P., Raffel L.J., Garchon H.-J., Jacob C.O., Serrano-Rios M.,
Martinez Larrad M.T., Teng W.-P., Park Y., Zhang Z.-X.,
Goldstein D.R., Tao Y.-W., Beaurain G., Bach J.-F., Huang H.-S.,
Luo D.-F., Zeidler A., Rotter J.I., Yang M.C.K., Modilevsky T.,
Maclaren N.K., She J.-X.;
"Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4
polymorphisms in multiple ethnic groups.";
Hum. Mol. Genet. 6:1275-1282(1997).
[27]
POLYMORPHISM, AND INVOLVEMENT IN CELIAC3.
PubMed=10189842; DOI=10.1136/gut.43.2.187;
Djilali-Saiah I., Schmitz J., Harfouch-Hammoud E., Mougenot J.-F.,
Bach J.-F., Caillat-Zucman S.;
"CTLA-4 gene polymorphism is associated with predisposition to coeliac
disease.";
Gut 43:187-189(1998).
[28]
VARIANT ALA-17, AND INVOLVEMENT IN THYROID ASSOCIATED ORBITOPATHY.
PubMed=10475192; DOI=10.1016/S0140-6736(99)01465-8;
Vaidya B., Imrie H., Perros P., Dickinson J., McCarthy M.I.,
Kendall-Taylor P., Pearce S.H.S.;
"Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers
susceptibility to thyroid associated orbitopathy.";
Lancet 354:743-744(1999).
[29]
POLYMORPHISM, VARIANT ALA-17, AND INVOLVEMENT IN GRAVES DISEASE.
PubMed=10924276; DOI=10.1006/mgme.2000.3007;
Chistyakov D.A., Savost'anov K.V., Turakulov R.I., Petunina N.A.,
Trukhina L.V., Kudinova A.V., Balabolkin M.I., Nosikov V.V.;
"Complex association analysis of Graves disease using a set of
polymorphic markers.";
Mol. Genet. Metab. 70:214-218(2000).
[30]
VARIANT ALA-17.
PubMed=10903931; DOI=10.1086/303059;
Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G.,
Kalachikov S., Cayanis E., Fischer S.G., Barst R.J., Hodge S.E.,
Knowles J.A.;
"Familial primary pulmonary hypertension (gene PPH1) is caused by
mutations in the bone morphogenetic protein receptor-II gene.";
Am. J. Hum. Genet. 67:737-744(2000).
[31]
POLYMORPHISM, AND INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS.
PubMed=15138458; DOI=10.1038/sj.ejhg.5201214;
Barreto M., Santos E., Ferreira R., Fesel C., Fontes M.F., Pereira C.,
Martins B., Andreia R., Viana J.F., Crespo F., Vasconcelos C.,
Ferreira C., Vicente A.M.;
"Evidence for CTLA4 as a susceptibility gene for systemic lupus
erythematosus.";
Eur. J. Hum. Genet. 12:620-626(2004).
[32]
POLYMORPHISM, INVOLVEMENT IN SUSCEPTIBILITY TO HBV INFECTION, AND
VARIANT ALA-17.
PubMed=15452244; DOI=10.1128/JVI.78.20.11258-11262.2004;
Thio C.L., Mosbruger T.L., Kaslow R.A., Karp C.L., Strathdee S.A.,
Vlahov D., O'Brien S.J., Astemborski J., Thomas D.L.;
"Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B
virus infection.";
J. Virol. 78:11258-11262(2004).
[33]
POLYMORPHISM, AND INVOLVEMENT IN CELIAC3.
PubMed=15657618; DOI=10.1038/sj.ejhg.5201357;
Hunt K.A., McGovern D.P.B., Kumar P.J., Ghosh S., Travis S.P.L.,
Walters J.R.F., Jewell D.P., Playford R.J., van Heel D.A.;
"A common CTLA4 haplotype associated with coeliac disease.";
Eur. J. Hum. Genet. 13:440-444(2005).
[34]
POLYMORPHISM, AND INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS.
PubMed=15688186; DOI=10.1007/s00439-004-1244-1;
Lee Y.H., Harley J.B., Nath S.K.;
"CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-
analysis.";
Hum. Genet. 116:361-367(2005).
[35]
POLYMORPHISM, INVOLVEMENT IN ALPS5, AND VARIANT ALPS5 TRP-70.
PubMed=25329329; DOI=10.1038/nm.3746;
Schubert D., Bode C., Kenefeck R., Hou T.Z., Wing J.B., Kennedy A.,
Bulashevska A., Petersen B.S., Schaeffer A.A., Gruening B.A.,
Unger S., Frede N., Baumann U., Witte T., Schmidt R.E., Dueckers G.,
Niehues T., Seneviratne S., Kanariou M., Speckmann C., Ehl S.,
Rensing-Ehl A., Warnatz K., Rakhmanov M., Thimme R., Hasselblatt P.,
Emmerich F., Cathomen T., Backofen R., Fisch P., Seidl M., May A.,
Schmitt-Graeff A., Ikemizu S., Salzer U., Franke A., Sakaguchi S.,
Walker L.S., Sansom D.M., Grimbacher B.;
"Autosomal dominant immune dysregulation syndrome in humans with CTLA4
mutations.";
Nat. Med. 20:1410-1416(2014).
[36]
POLYMORPHISM, AND INVOLVEMENT IN ALPS5.
PubMed=25213377; DOI=10.1126/science.1255904;
Kuehn H.S., Ouyang W., Lo B., Deenick E.K., Niemela J.E., Avery D.T.,
Schickel J.N., Tran D.Q., Stoddard J., Zhang Y., Frucht D.M.,
Dumitriu B., Scheinberg P., Folio L.R., Frein C.A., Price S., Koh C.,
Heller T., Seroogy C.M., Huttenlocher A., Rao V.K., Su H.C.,
Kleiner D., Notarangelo L.D., Rampertaap Y., Olivier K.N., McElwee J.,
Hughes J., Pittaluga S., Oliveira J.B., Meffre E., Fleisher T.A.,
Holland S.M., Lenardo M.J., Tangye S.G., Uzel G.;
"Immune dysregulation in human subjects with heterozygous germline
mutations in CTLA4.";
Science 345:1623-1627(2014).
-!- FUNCTION: Inhibitory receptor acting as a major negative regulator
of T-cell responses. The affinity of CTLA4 for its natural B7
family ligands, CD80 and CD86, is considerably stronger than the
affinity of their cognate stimulatory coreceptor CD28.
{ECO:0000269|PubMed:16551244, ECO:0000269|PubMed:1714933}.
-!- SUBUNIT: Homodimer; disulfide-linked (PubMed:11279501,
PubMed:11279502, Ref.23, PubMed:21156796, PubMed:28484017). Binds
to CD80/B7-1 and CD86/B7.2 (PubMed:11279501, PubMed:11279502,
PubMed:28484017). Interacts with ICOSLG (PubMed:28484017).
{ECO:0000269|PubMed:11279501, ECO:0000269|PubMed:11279502,
ECO:0000269|PubMed:21156796, ECO:0000269|PubMed:28484017,
ECO:0000269|Ref.23}.
-!- INTERACTION:
P33681:CD80; NbExp=3; IntAct=EBI-1030991, EBI-1031024;
P42081:CD86; NbExp=3; IntAct=EBI-1030991, EBI-1030956;
P27986:PIK3R1; NbExp=3; IntAct=EBI-1030991, EBI-79464;
-!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18468488,
ECO:0000269|PubMed:28484017}; Single-pass type I membrane protein
{ECO:0000269|PubMed:18468488, ECO:0000269|PubMed:28484017}.
Note=Exists primarily an intracellular antigen whose surface
expression is tightly regulated by restricted trafficking to the
cell surface and rapid internalisation;.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=5;
Name=1;
IsoId=P16410-1; Sequence=Displayed;
Name=2; Synonyms=ss-CTLA-4;
IsoId=P16410-2; Sequence=VSP_041284;
Name=3;
IsoId=P16410-3; Sequence=VSP_041284, VSP_041287;
Name=4;
IsoId=P16410-4; Sequence=VSP_041285, VSP_041286, VSP_041287;
Name=5;
IsoId=P16410-5; Sequence=VSP_047238, VSP_047239;
-!- TISSUE SPECIFICITY: Widely expressed with highest levels in
lymphoid tissues. Detected in activated T-cells where expression
levels are 30- to 50-fold less than CD28, the stimulatory
coreceptor, on the cell surface following activation.
{ECO:0000269|PubMed:10493833, ECO:0000269|PubMed:16551244,
ECO:0000269|PubMed:1713603}.
-!- PTM: N-glycosylation is important for dimerization.
{ECO:0000269|PubMed:11279502, ECO:0000269|PubMed:16002699,
ECO:0000269|PubMed:21156796}.
-!- PTM: Phosphorylation at Tyr-201 prevents binding to the AP-2
adapter complex, blocks endocytosis, and leads to retention of
CTLA4 on the cell surface. {ECO:0000269|PubMed:10842319,
ECO:0000269|PubMed:9175836, ECO:0000269|PubMed:9813138}.
-!- POLYMORPHISM: Genetic variations in CTLA4 are associated with
susceptibility to several autoimmune disorders (PubMed:18595775,
PubMed:12724780, PubMed:10189842, PubMed:10924276,
PubMed:15138458, PubMed:15657618, PubMed:15688186,
PubMed:25329329, PubMed:25213377). They influence responsiveness
to hepatitis B virus (HBV) infection [MIM:610424]
(PubMed:15452244). {ECO:0000269|PubMed:10189842,
ECO:0000269|PubMed:10924276, ECO:0000269|PubMed:12724780,
ECO:0000269|PubMed:15138458, ECO:0000269|PubMed:15452244,
ECO:0000269|PubMed:15657618, ECO:0000269|PubMed:15688186,
ECO:0000269|PubMed:18595775, ECO:0000269|PubMed:25213377,
ECO:0000269|PubMed:25329329}.
-!- DISEASE: Systemic lupus erythematosus (SLE) [MIM:152700]: A
chronic, relapsing, inflammatory, and often febrile multisystemic
disorder of connective tissue, characterized principally by
involvement of the skin, joints, kidneys and serosal membranes. It
is of unknown etiology, but is thought to represent a failure of
the regulatory mechanisms of the autoimmune system. The disease is
marked by a wide range of system dysfunctions, an elevated
erythrocyte sedimentation rate, and the formation of LE cells in
the blood or bone marrow. {ECO:0000269|PubMed:15138458,
ECO:0000269|PubMed:15688186}. Note=Disease susceptibility is
associated with variations affecting the gene represented in this
entry.
-!- DISEASE: Note=Genetic variations in CTLA4 may influence
susceptibility to Graves disease, an autoimmune disorder
associated with overactivity of the thyroid gland and
hyperthyroidism. {ECO:0000269|PubMed:10924276}.
-!- DISEASE: Diabetes mellitus, insulin-dependent, 12 (IDDM12)
[MIM:601388]: A multifactorial disorder of glucose homeostasis
that is characterized by susceptibility to ketoacidosis in the
absence of insulin therapy. Clinical features are polydipsia,
polyphagia and polyuria which result from hyperglycemia-induced
osmotic diuresis and secondary thirst. These derangements result
in long-term complications that affect the eyes, kidneys, nerves,
and blood vessels. {ECO:0000269|PubMed:9259273}. Note=Disease
susceptibility is associated with variations affecting the gene
represented in this entry.
-!- DISEASE: Celiac disease 3 (CELIAC3) [MIM:609755]: A
multifactorial, chronic disorder of the small intestine caused by
intolerance to gluten. It is characterized by immune-mediated
enteropathy associated with failed intestinal absorption, and
malnutrition. In predisposed individuals, the ingestion of gluten-
containing food such as wheat and rye induces a flat jejunal
mucosa with infiltration of lymphocytes.
{ECO:0000269|PubMed:10189842, ECO:0000269|PubMed:15657618}.
Note=Disease susceptibility is associated with variations
affecting the gene represented in this entry.
-!- DISEASE: Autoimmune lymphoproliferative syndrome 5 (ALPS5)
[MIM:616100]: An autosomal dominant primary immunodeficiency
characterized by severe autoimmunity, infiltration of non-lymphoid
organs, such as the intestine, lungs and brain, by hyperactive T
cells and B cells, autoimmune cytopenias, and
hypogammaglobulinemia in early childhood.
{ECO:0000269|PubMed:25213377, ECO:0000269|PubMed:25329329}.
Note=The disease is caused by mutations affecting the gene
represented in this entry.
-!- PHARMACEUTICAL: Engineered fusion proteins consisting of the
extracellular domain of CTLA4 and the IgG Fc region (Ctla4-Ig),
inhibit T-cell-dependent antibody responses, and are used as
immunosuppressive agents. They are soluble, have an enhanced
affinity for B7 ligands and act as a competitive inhibitor of
CD28.
-!- MISCELLANEOUS: The therapeutic antibody Ipilimumab competes for
the binding site of the endogenous ligands CD80/B7-1, CD86/B7-2
and ICOSLG.
-!- WEB RESOURCE: Name=Wikipedia; Note=CLTA-4 entry;
URL="https://en.wikipedia.org/wiki/CTLA-4";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; L15006; AAB59385.1; -; mRNA.
EMBL; M74363; AAA52127.1; -; Genomic_DNA.
EMBL; AF411058; AAL40932.1; -; Genomic_DNA.
EMBL; AY792514; AAV66331.1; -; mRNA.
EMBL; AY999702; AAY00166.1; -; mRNA.
EMBL; DQ785106; ABG85285.1; -; mRNA.
EMBL; AF414120; AAL07473.1; -; mRNA.
EMBL; DQ357942; ABC67470.1; -; Genomic_DNA.
EMBL; AC010138; AAX93176.1; -; Genomic_DNA.
EMBL; BC074842; AAH74842.1; -; mRNA.
EMBL; BC074893; AAH74893.1; -; mRNA.
EMBL; AH002733; AAA52773.1; -; Genomic_DNA.
EMBL; U90273; AAD00698.1; -; mRNA.
EMBL; AF142144; AAF02499.1; -; Genomic_DNA.
CCDS; CCDS2362.1; -. [P16410-1]
CCDS; CCDS42803.1; -. [P16410-5]
PIR; S08614; S08614.
RefSeq; NP_001032720.1; NM_001037631.2. [P16410-5]
RefSeq; NP_005205.2; NM_005214.4. [P16410-1]
UniGene; Hs.247824; -.
PDB; 1AH1; NMR; -; A=37-161.
PDB; 1H6E; X-ray; 3.60 A; P=197-207.
PDB; 1I85; X-ray; 3.20 A; C/D=36-161.
PDB; 1I8L; X-ray; 3.00 A; C/D=36-161.
PDB; 2X44; X-ray; 2.60 A; D=36-161.
PDB; 3BX7; X-ray; 2.10 A; C=38-161.
PDB; 3OSK; X-ray; 1.80 A; A/B=36-161.
PDB; 5GGV; X-ray; 2.00 A; Y=36-161.
PDB; 5TRU; X-ray; 3.00 A; C/c=37-154.
PDBsum; 1AH1; -.
PDBsum; 1H6E; -.
PDBsum; 1I85; -.
PDBsum; 1I8L; -.
PDBsum; 2X44; -.
PDBsum; 3BX7; -.
PDBsum; 3OSK; -.
PDBsum; 5GGV; -.
PDBsum; 5TRU; -.
ProteinModelPortal; P16410; -.
SMR; P16410; -.
BioGrid; 107875; 109.
DIP; DIP-35607N; -.
ELM; P16410; -.
IntAct; P16410; 11.
MINT; P16410; -.
STRING; 9606.ENSP00000303939; -.
ChEMBL; CHEMBL2364164; -.
DrugBank; DB06186; Ipilimumab.
GuidetoPHARMACOLOGY; 2743; -.
iPTMnet; P16410; -.
PhosphoSitePlus; P16410; -.
BioMuta; CTLA4; -.
DMDM; 27735177; -.
PaxDb; P16410; -.
PeptideAtlas; P16410; -.
PRIDE; P16410; -.
Ensembl; ENST00000295854; ENSP00000295854; ENSG00000163599. [P16410-5]
Ensembl; ENST00000302823; ENSP00000303939; ENSG00000163599. [P16410-1]
Ensembl; ENST00000472206; ENSP00000417779; ENSG00000163599. [P16410-4]
GeneID; 1493; -.
KEGG; hsa:1493; -.
UCSC; uc002vak.3; human. [P16410-1]
CTD; 1493; -.
DisGeNET; 1493; -.
EuPathDB; HostDB:ENSG00000163599.14; -.
GeneCards; CTLA4; -.
HGNC; HGNC:2505; CTLA4.
MalaCards; CTLA4; -.
MIM; 109100; phenotype.
MIM; 123890; gene.
MIM; 152700; phenotype.
MIM; 601388; phenotype.
MIM; 609755; phenotype.
MIM; 610424; phenotype.
MIM; 616100; phenotype.
neXtProt; NX_P16410; -.
OpenTargets; ENSG00000163599; -.
Orphanet; 555; Celiac disease.
Orphanet; 900; Granulomatosis with polyangiitis.
Orphanet; 855; Hashimoto struma.
Orphanet; 536; Systemic lupus erythematosus.
PharmGKB; PA27006; -.
eggNOG; ENOG410IJ05; Eukaryota.
eggNOG; ENOG410YUQR; LUCA.
GeneTree; ENSGT00530000063873; -.
HOGENOM; HOG000112047; -.
HOVERGEN; HBG057978; -.
InParanoid; P16410; -.
KO; K06538; -.
OMA; FSKGMHV; -.
OrthoDB; EOG091G0IGY; -.
PhylomeDB; P16410; -.
TreeFam; TF335679; -.
Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
Reactome; R-HSA-8877330; RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs).
SIGNOR; P16410; -.
EvolutionaryTrace; P16410; -.
GeneWiki; CTLA-4; -.
GenomeRNAi; 1493; -.
PRO; PR:P16410; -.
Proteomes; UP000005640; Chromosome 2.
Bgee; ENSG00000163599; -.
CleanEx; HS_CTLA4; -.
ExpressionAtlas; P16410; baseline and differential.
Genevisible; P16410; HS.
GO; GO:0045334; C:clathrin-coated endocytic vesicle; IDA:BHF-UCL.
GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
GO; GO:0005794; C:Golgi apparatus; IDA:BHF-UCL.
GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
GO; GO:0005886; C:plasma membrane; TAS:Reactome.
GO; GO:0098636; C:protein complex involved in cell adhesion; IDA:MGI.
GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
GO; GO:0050853; P:B cell receptor signaling pathway; IMP:UniProtKB.
GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
GO; GO:0006955; P:immune response; TAS:ProtInc.
GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:UniProtKB.
GO; GO:0050777; P:negative regulation of immune response; IEA:Ensembl.
GO; GO:0045590; P:negative regulation of regulatory T cell differentiation; IDA:BHF-UCL.
GO; GO:0042130; P:negative regulation of T cell proliferation; IEA:Ensembl.
GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
GO; GO:0045589; P:regulation of regulatory T cell differentiation; TAS:Reactome.
GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
Gene3D; 2.60.40.10; -; 1.
InterPro; IPR008096; CTLA4.
InterPro; IPR036179; Ig-like_dom_sf.
InterPro; IPR013783; Ig-like_fold.
InterPro; IPR003599; Ig_sub.
InterPro; IPR013106; Ig_V-set.
PANTHER; PTHR11494:SF8; PTHR11494:SF8; 1.
Pfam; PF07686; V-set; 1.
PRINTS; PR01720; CTLANTIGEN4.
SMART; SM00409; IG; 1.
SMART; SM00406; IGv; 1.
SUPFAM; SSF48726; SSF48726; 1.
1: Evidence at protein level;
3D-structure; Adaptive immunity; Alternative splicing; Cell membrane;
Complete proteome; Diabetes mellitus; Disease mutation;
Disulfide bond; Glycoprotein; Immunity; Immunoglobulin domain;
Membrane; Pharmaceutical; Phosphoprotein; Polymorphism;
Reference proteome; Signal; Systemic lupus erythematosus;
Transmembrane; Transmembrane helix.
SIGNAL 1 35 {ECO:0000255}.
CHAIN 36 223 Cytotoxic T-lymphocyte protein 4.
/FTId=PRO_0000014734.
TOPO_DOM 36 161 Extracellular.
{ECO:0000305|PubMed:28484017}.
TRANSMEM 162 182 Helical. {ECO:0000255}.
TOPO_DOM 183 223 Cytoplasmic. {ECO:0000255}.
DOMAIN 39 140 Ig-like V-type.
REGION 46 50 Homodimerization.
{ECO:0000269|PubMed:21156796}.
REGION 134 139 Important for interaction with CD80 and
CD86. {ECO:0000269|PubMed:28484017}.
REGION 150 155 Homodimerization.
{ECO:0000269|PubMed:21156796,
ECO:0000269|PubMed:28484017}.
MOD_RES 201 201 Phosphotyrosine; by TXK and JAK2.
{ECO:0000269|PubMed:10842319,
ECO:0000269|PubMed:9175836,
ECO:0000269|PubMed:9813138}.
CARBOHYD 113 113 N-linked (GlcNAc...) asparagine.
{ECO:0000269|PubMed:11279502,
ECO:0000269|PubMed:16002699,
ECO:0000269|PubMed:21156796}.
CARBOHYD 145 145 N-linked (GlcNAc...) asparagine.
{ECO:0000269|PubMed:11279502,
ECO:0000269|PubMed:16002699}.
DISULFID 58 129 {ECO:0000244|PDB:3BX7,
ECO:0000244|PDB:5TRU,
ECO:0000269|PubMed:11279501,
ECO:0000269|PubMed:11279502,
ECO:0000269|PubMed:21156796,
ECO:0000269|PubMed:28484017,
ECO:0000269|PubMed:9228944,
ECO:0000269|Ref.23}.
DISULFID 85 103 {ECO:0000244|PDB:3BX7,
ECO:0000244|PDB:5TRU,
ECO:0000269|PubMed:11279501,
ECO:0000269|PubMed:11279502,
ECO:0000269|PubMed:21156796,
ECO:0000269|PubMed:28484017,
ECO:0000269|PubMed:9228944,
ECO:0000269|Ref.23}.
DISULFID 157 157 Interchain. {ECO:0000244|PDB:3BX7,
ECO:0000269|PubMed:28484017,
ECO:0000269|Ref.23}.
VAR_SEQ 38 204 Missing (in isoform 2 and isoform 3).
{ECO:0000303|PubMed:18595775}.
/FTId=VSP_041284.
VAR_SEQ 58 58 C -> S (in isoform 4).
{ECO:0000303|PubMed:18595775}.
/FTId=VSP_041285.
VAR_SEQ 59 204 Missing (in isoform 4).
{ECO:0000303|PubMed:18595775}.
/FTId=VSP_041286.
VAR_SEQ 153 174 DPEPCPDSDFLLWILAAVSSGL -> AKEKKPSYNRGLCEN
APNRARM (in isoform 5).
{ECO:0000303|Ref.9}.
/FTId=VSP_047238.
VAR_SEQ 175 223 Missing (in isoform 5).
{ECO:0000303|Ref.9}.
/FTId=VSP_047239.
VAR_SEQ 205 223 PPTEPECEKQFQPYFIPIN -> KEKKPSYNRGLCENAPNR
ARM (in isoform 3 and isoform 4).
{ECO:0000303|PubMed:18595775}.
/FTId=VSP_041287.
VARIANT 17 17 T -> A (increased risk for Graves
disease, insulin-dependent diabetes
mellitus, thyroid-associated orbitopathy,
systemic lupus erythematosus and
susceptibility to HBV infection;
dbSNP:rs231775).
{ECO:0000269|PubMed:10475192,
ECO:0000269|PubMed:10903931,
ECO:0000269|PubMed:10924276,
ECO:0000269|PubMed:15452244,
ECO:0000269|PubMed:1713603,
ECO:0000269|PubMed:18595775,
ECO:0000269|PubMed:9259273}.
/FTId=VAR_013577.
VARIANT 70 70 R -> W (in ALPS5; dbSNP:rs606231422).
{ECO:0000269|PubMed:25329329}.
/FTId=VAR_072681.
MUTAGEN 45 45 V->D: Strongly reduced interaction with
CD80, CD86 and ICOSLG.
{ECO:0000269|PubMed:28484017}.
MUTAGEN 47 47 L->D: Strongly reduced interaction with
CD80, CD86 and ICOSLG.
{ECO:0000269|PubMed:28484017}.
MUTAGEN 49 49 S->A: Strongly reduced interaction with
CD80, CD86 and ICOSLG.
{ECO:0000269|PubMed:28484017}.
MUTAGEN 70 70 R->A,D: Strongly reduced interaction with
CD80, CD86 and ICOSLG.
{ECO:0000269|PubMed:28484017}.
MUTAGEN 130 130 K->A,D: Strongly reduced interaction with
CD80, CD86 and ICOSLG.
{ECO:0000269|PubMed:28484017}.
MUTAGEN 132 132 E->A,R: Strongly reduced interaction with
CD80, CD86 and ICOSLG.
{ECO:0000269|PubMed:28484017}.
MUTAGEN 139 139 Y->A,D: Strongly reduced interaction with
CD80, CD86 and ICOSLG.
{ECO:0000269|PubMed:28484017}.
MUTAGEN 143 143 I->A,D: Strongly reduced interaction with
CD80, CD86 and ICOSLG.
{ECO:0000269|PubMed:28484017}.
CONFLICT 37 37 A -> V (in Ref. 3; ABG85285).
{ECO:0000305}.
CONFLICT 147 147 T -> A (in Ref. 8; AAA52773).
{ECO:0000305}.
STRAND 39 41 {ECO:0000244|PDB:5GGV}.
STRAND 44 47 {ECO:0000244|PDB:3OSK}.
STRAND 50 52 {ECO:0000244|PDB:1I8L}.
STRAND 54 60 {ECO:0000244|PDB:3OSK}.
STRAND 64 66 {ECO:0000244|PDB:1I85}.
STRAND 68 77 {ECO:0000244|PDB:3OSK}.
STRAND 80 90 {ECO:0000244|PDB:3OSK}.
STRAND 102 108 {ECO:0000244|PDB:3OSK}.
STRAND 111 116 {ECO:0000244|PDB:3OSK}.
HELIX 121 123 {ECO:0000244|PDB:3OSK}.
STRAND 125 138 {ECO:0000244|PDB:3OSK}.
STRAND 140 143 {ECO:0000244|PDB:3OSK}.
STRAND 147 150 {ECO:0000244|PDB:3OSK}.
STRAND 156 158 {ECO:0000244|PDB:1AH1}.
SEQUENCE 223 AA; 24656 MW; 6F9466FB2E139A5A CRC64;
MACLGFQRHK AQLNLATRTW PCTLLFFLLF IPVFCKAMHV AQPAVVLASS RGIASFVCEY
ASPGKATEVR VTVLRQADSQ VTEVCAATYM MGNELTFLDD SICTGTSSGN QVNLTIQGLR
AMDTGLYICK VELMYPPPYY LGIGNGTQIY VIDPEPCPDS DFLLWILAAV SSGLFFYSFL
LTAVSLSKML KKRSPLTTGV YVKMPPTEPE CEKQFQPYFI PIN


Related products :

Catalog number Product name Quantity
E1230m ELISA kit Cd152,Ctla4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Mouse,Mus musculus 96T
U1230m CLIA Cd152,Ctla4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Mouse,Mus musculus 96T
E1230m ELISA Cd152,Ctla4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Mouse,Mus musculus 96T
U1230h CLIA CD152,CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Homo sapiens,Human 96T
E1230h ELISA CD152,CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Homo sapiens,Human 96T
E1230h ELISA kit CD152,CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Homo sapiens,Human 96T
10-663-45197 Cytotoxic T-Lymphocyte Associated Antigen-4_Fc Chimera (CTLA-4) Human - Cytotoxic T-lymphocyte-associated antigen 4; CTLA-4; CD152 antigen N_A 0.01 mg
10-663-45197 Cytotoxic T-Lymphocyte Associated Antigen-4_Fc Chimera (CTLA-4) Human - Cytotoxic T-lymphocyte-associated antigen 4; CTLA-4; CD152 antigen N_A 0.05 mg
10-663-45197 Cytotoxic T-Lymphocyte Associated Antigen-4_Fc Chimera (CTLA-4) Human - Cytotoxic T-lymphocyte-associated antigen 4; CTLA-4; CD152 antigen N_A 1 mg
U1230Rb CLIA CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Oryctolagus cuniculus,Rabbit 96T
E1230Rb ELISA CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Oryctolagus cuniculus,Rabbit 96T
E1230Rb ELISA kit CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Oryctolagus cuniculus,Rabbit 96T
U1230p CLIA CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Pig,Sus scrofa 96T
E1230p ELISA kit CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Pig,Sus scrofa 96T
E1230p ELISA CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Pig,Sus scrofa 96T
228-10291-1 Recombinant Human Cytotoxic T-Lymphocyte Associated Antigen-4 (CTLA-4) _ CD152 5
228-10291-2 Recombinant Human Cytotoxic T-Lymphocyte Associated Antigen-4 (CTLA-4) _ CD152 25
128-10063-2 Hamster Anti Mouse Cytotoxic T-Lymphocyte Associated Antigen-4 (CTLA-4) _ CD152 1 mg
E1230c ELISA Canis familiaris,Canis lupus familiaris,CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Dog 96T
U1230c CLIA Canis familiaris,Canis lupus familiaris,CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Dog 96T
E1230c ELISA kit Canis familiaris,Canis lupus familiaris,CTLA4,CTLA-4,Cytotoxic T-lymphocyte protein 4,Cytotoxic T-lymphocyte-associated antigen 4,Dog 96T
ELH-CTLA4-001 Custom Human Cytotoxic T-Lymphocyte Associated Antigen-4 (CTLA-4) _ CD152 ELISA Kit available on demand 1 X 96 well strip plate
20-272-191914 CTLA4 - Mouse monoclonal [BNI3] to CTLA4; Cytotoxic T-lymphocyte-associated antigen 4; CTLA-4; CD152 antigen Monoclonal 0.1 mg
E12410713 Rat cytotoxic T lymphocyte associated antigen 4(CTLA-4) ELISA Kit 1
10-288-21033F Interleukin-17A - IL-17A; IL-17; Cytotoxic T-lymphocyte-associated antigen 8; CTLA-8 0.1 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur